Selskapsdetaljer

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. Net sales (not including sold divisions) break down by activity as follows:
  • development of solutions and diagnostic services (51.8%). The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
  • manufacture and sale of molecular screening kits (48.2%; Primerdesign): for laboratories.
The geographical breakdown of sales is as follows: Europe (42%), Asia-Pacific (19.5%), America (20.4%), Middle East (10.5%) and Africa (7.6%). In December 2019, the group sold its cytology solution activity (NOVAprep®).

Kilde: Cofisem - Sist oppdatert: 02 Nov 2020
Ledelse
Chief Executive Officer Graham Mullis
Chief Financial Officer Anthony Dyer
Investor Relations Director Mandy Cowling
Development Paul Eros
Chief Operations Officer Lisa Henriet
Human Resources Director Wendy Karban
Kilde: Cofisem - Sist oppdatert: 13 Jul 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales 13,081 13,721 14,954 11,076 8,892
Consumed purchases 4,758 3,520 0
Personnal costs 4,318 3,603 4,248 3,086
Operating profit -1,776 -1,385 -4,071 -4,463 -13,185
Income tax -8 32 -2 2 1
Net income -6,558 -4,738 -5,442 -5,711 -13,908
Net consolidated income (Group share) -6,558 -4,738 -5,442 -5,711 -13,908
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Kilde: Cofisem - Sist oppdatert: 02 Nov 2020
Største aksjonærer
ABN Amro Bank 17.70 %
Legal and General Group 6.70 %
Talence Selection 3.90 %
Kilde: Cofisem - Sist oppdatert: 07 Jun 2019

Adresse

Novacyt

13 Avenue Morane Saulnier
FR-78140 Vélizy-Villacoublay
France
Kilde: Cofisem - Sist oppdatert: 02 Nov 2020

Kontakt

Graham Mullis
Telefonnummer: + 44 (0)7901 5141 21
Kilde: Novacyt - Sist oppdatert: 02 Nov 2020